Clinical Trial Update: Study of PIT565 in Relapsed and/or Refractory B-cell Malignancies [Phase 1]

View source ↗

Summary

Phase 1 study evaluating PIT565 in relapsed/refractory B-cell malignancies, including B-cell Non-Hodgkin Lymphoma and B-cell Acute Lymphoblastic Leukemia.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• B-cell Acute Lymphoblastic Leukemia
• B-cell Non-hodgkin Lymphoma

Drugs mentioned

• PIT565 (PIT565)

Snippet

Sponsor: Novartis Pharmaceuticals | Conditions: B-cell Non-Hodgkin Lymphoma (B-NHL), B-cell Acute Lymphoblastic Leukemia (B-ALL) | Phase 1 | Status: ACTIVE_NOT_RECRUITING